A Comparative Study of Remimazolam Administration Methods for Sedation

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0011590

Enrollment

Registered

2026-02-09

Start date

2026-02-11

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : 1) Continuous infusion (CI) group Remimazolam is administered at a rate of 3 mg·kg?¹·h?¹ until a Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score of 4 is achieved. Thereaft

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A. Adult patients aged 19 years or older B. Patients classified as American Society of Anesthesiologists (ASA) physical status I–III

Exclusion criteria

Exclusion criteria: A. Patients with liver cirrhosis or end-stage renal disease requiring dialysis B. Patients with a history of neurological or psychiatric disorders C. Patients with known allergies to study medications (benzodiazepines or opioids) D. Patients with alcohol dependence or substance abuse E. Pregnant women F. Patients unwilling to participate in the study

Design outcomes

Primary

Measure	Time frame
Time from discontinuation of remimazolam administration to recovery of consciousness	—

Secondary

Measure	Time frame
The total amount of remimazolam administered (mg·kg?¹·h?¹) from initiation to discontinuation of infusion	—

Countries

Korea, Republic of

Contacts

Public ContactSou-Hyun Lee

Kyungpook National University Hospital

youlion6@gmail.com+82-53-200-5863

Outcome results